At the AACC Show 2014
September 2014—Currently in development from Abbott is the Iridica platform, targeted for release in CE-marked European countries within 12 months, to test for and identify hundreds of bacteria and candida, fungi, and viruses from a direct patient specimen. The benchtop system is designed to complete testing in eight hours, giving clinicians the ability to obtain test results sooner than conventional methods in order to prescribe more accurate antimicrobial drugs or other therapies.
At its booth, Abbott featured a variety of innovations focused on increased testing volumes and improving efficiencies in four realms of the laboratory. For the core laboratory, the Accelerator a3600 doubles per-hour processing capacity, compared to previous systems. Studies have shown that when a core lab partners with Abbott, it can eliminate a significant percentage of associated operating costs through automation and standardization of testing. In molecular testing, the m2000 RealTime System for automated infectious disease testing gives labs the ability to handle greater volumes on a single platform.
The i-Stat System is a point-of-care, handheld blood analyzer that allows users to quickly and accurately analyze lab-quality results within minutes to accelerate decisionmaking and ensure patients receive effective and efficient care.
Abbott also provides laboratories with a powerful suite of informatics solutions to manage large volumes of data across health care systems, helping labs simplify complex processes to make information actionable.
Abbott, 847-937-6100